From the Food and Drug Administration

JAMA. 1998 Sep 9;280(10):872. doi: 10.1001/jama.280.10.872-jfd80008-2-1.
No abstract available

MeSH terms

  • Drug Approval
  • Erythema Nodosum / drug therapy*
  • Humans
  • Leprostatic Agents / therapeutic use*
  • Leprosy, Lepromatous / drug therapy*
  • Policy Making
  • Thalidomide / therapeutic use*
  • United States
  • United States Food and Drug Administration / organization & administration*

Substances

  • Leprostatic Agents
  • Thalidomide